Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone
- PMID: 1623905
- DOI: 10.1007/BF00265929
Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone
Abstract
The effects of three different enzyme-inducing drugs (antipyrine 1200 mg, phenobarbital 100 mg, rifampicin 600 mg per day for 7 days) on plasma and urinary testosterone concentrations, plasma gonadotropin levels, antipyrine kinetics, and urinary 6 beta-hydroxycortisol excretion were studied in 18 healthy volunteers. Changes in plasma and urinary testosterone concentrations following exogenous testosterone undecanoate (TU) were also investigated. Although both antipyrine and rifampicin increased antipyrine clearance by about 60%, they produced contrary effects on testosterone: antipyrine lowered the total morning plasma testosterone and plasma testosterone AUC following TU, while rifampicin led to increases of about 20% and 78%, respectively. By contrast, phenobarbital did not significantly alter the endogenous and exogenous plasma testosterone concentrations, but it increased the urinary excretion of testosterone by more than 60%. The other two enzyme inducers did not alter this parameter. Gonadotropin levels remained unchanged. The results indicate that different enzyme-inducing agents exert divergent effects on endogenous and exogenous testosterone concentrations and suggest that the effect of enzyme induction on endogenous testosterone depends on the type of microsomal enzyme-inducing drug used rather than on the extent of the induction achieved.
Similar articles
-
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.Eur J Clin Pharmacol. 1979 Mar 26;15(2):139-45. doi: 10.1007/BF00609878. Eur J Clin Pharmacol. 1979. PMID: 35353 No abstract available.
-
The effect of antipyrine, phenobarbitol and rifampicin on thyroid hormone metabolism in man.Eur J Clin Invest. 1981 Oct;11(5):381-7. doi: 10.1111/j.1365-2362.1981.tb02000.x. Eur J Clin Invest. 1981. PMID: 6800809 Clinical Trial.
-
Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man.Eur J Clin Pharmacol. 1983;24(2):247-50. doi: 10.1007/BF00613826. Eur J Clin Pharmacol. 1983. PMID: 6840175
-
Clinical implications of enzyme induction and enzyme inhibition.Clin Pharmacokinet. 1981 Jan-Feb;6(1):1-24. doi: 10.2165/00003088-198106010-00001. Clin Pharmacokinet. 1981. PMID: 6113907 Review.
-
Drug control of steroid metabolism by the hepatic endoplasmic reticulum.Drug Metab Rev. 1983;14(6):1119-44. doi: 10.3109/03602538308991424. Drug Metab Rev. 1983. PMID: 6373207 Review.
Cited by
-
Clinical pharmacokinetic considerations in the elderly. An update.Clin Pharmacokinet. 1997 Oct;33(4):302-12. doi: 10.2165/00003088-199733040-00005. Clin Pharmacokinet. 1997. PMID: 9342505 Review.
-
Pharmacokinetic interactions with rifampicin : clinical relevance.Clin Pharmacokinet. 2003;42(9):819-50. doi: 10.2165/00003088-200342090-00003. Clin Pharmacokinet. 2003. PMID: 12882588 Review.
-
Endocrine disrupting contaminants--beyond the dogma.Environ Health Perspect. 2006 Apr;114 Suppl 1(Suppl 1):9-12. doi: 10.1289/ehp.8045. Environ Health Perspect. 2006. PMID: 16818240 Free PMC article. Review.
-
SXR, a novel steroid and xenobiotic-sensing nuclear receptor.Genes Dev. 1998 Oct 15;12(20):3195-205. doi: 10.1101/gad.12.20.3195. Genes Dev. 1998. PMID: 9784494 Free PMC article.
-
Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.Eur J Clin Pharmacol. 2003 Dec;59(10):713-33. doi: 10.1007/s00228-003-0690-3. Epub 2003 Nov 6. Eur J Clin Pharmacol. 2003. PMID: 14605790 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources